Journal article icon

Journal article

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.

Abstract:

BACKGROUND: Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGFβ and VEGF receptors that is licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Current evidence-based post-nephrectomy management of individuals with localized RCC consists of surveillance-based follow up. The SORCE trial is designed to investigate whether treatment with adjuvant sorafenib can reduce recurrence rates in this cohort. CASE PRESENTATION: Her...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1186/1471-2407-12-590

Authors


Fairfax, BP More by this author
Roberts, IS More by this author
Collier, J More by this author
Expand authors...
Medical Research Council More from this funder
Publisher:
BioMed Central Ltd. Publisher's website
Journal:
BMC cancer Journal website
Volume:
12
Issue:
1
Pages:
590
Publication date:
2012
DOI:
EISSN:
1471-2407
ISSN:
1471-2407
URN:
uuid:c39bf31a-0eb7-4f72-9a3a-0baeac09982d
Source identifiers:
367749
Local pid:
pubs:367749

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP